Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ModraDoc006/ritonavir with radiotherapy and ADT in high-risk prostate cancer
NL-OMON55802Phase 1Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ModraDoc006 and ritonavir in prostate cancer (PCa), sponsored by Netherlands Cancer Institute. Primary endpoint: Maximum tolerated dose. Started Feb 2017; status: active, not recruiting.
02
Drugs
ModraDoc006ritonavir
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON55802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55802.